A new paper, published by the team led by Dr. David Cowan at the WADA-Accredited Drug Control Centre at King’s College London, has been published in “Rapid Communications in Mass Spectrometry.”
The research focuses on the usage of P-III-NP as a biomarker to detect growth hormone in human serum.
Danielle Moncrieffe, an investigator on the project (and recent winner of the prestigious ‘Barber Prize’) highlights the importance of this work:
“As one of two biomarkers for detecting rhGH administration in sport the analytical measurement of Procollagen III amino-terminal propeptide (P-III-NP) in serum is invaluable to the science of anti-doping. To complement the existing immunoassay approaches currently used, we have initiated the development of a quantitative mass spectrometric (MS) method for P-III-NP through the partial characterization of the protein to propose two surrogate tryptic peptides for measurement. For these peptides (hT1 and T5) sensitive micro- and nano- liquid chromatography-MS (LC-MS) methods have been developed, which has facilitated the detection of P-III-NP in a human serum sample by MS for the first time”.
The article, titled “Peptide Selection for the Quantification of P-III-NP in Human Serum by Mass Spectrometry,” can be accessed online, using the link http://onlinelibrary.wiley.com/doi/10.1002/rcm.8066/abstract;jsessionid=5D81C07FC5170EEE9E1CB421E5DDF08E.f04t01.
For questions about this research or other PCC funded projects, contact Jenna Celmer at email@example.com.